Skip to main content

Advertisement

SpringerLink
Log in

Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker

  • Clinical Study - Patient Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

The purpose of this study was to assess the usefulness of diffusion weighted imaging as an additional imaging biomarker for treatment response in recurrent/progressive malignant gliomas treated with bevacizumab alone or in combination with other chemotherapeutic agents. Twenty patients treated with bevacizumab alone or concurrent chemotherapy were followed up with serial MR imaging. Volume and ADC values of contrast enhancing lesion (CELvol, CELADC) and also of non-enhancing lesion (NELvol, NELADC) were obtained. CELvol showed a progressive decrease in non-progressors with a median percentage change of −73.2% (P = 0.001) as compared to −33.4% for progressors by 1 year/last imaging (P = 0.382). NELvol also showed a decrease in non-progressors on follow up imaging though only significant for 3 months follow up (P = 0.042). In progressors, CELvol and NELvol showed initial decrease followed by slight increase by 1 year/last imaging though not significant (P value of 0.382 and 0.46, respectively). CELADC and NELADC in non-progressors did not show any statistically significant change though there was slight trend for positive percent change especially for CELADC by 1 year/last imaging follow up study (P value of 0.077 and 0.339, respectively). Progressors showed a progressive negative percent change of CELADC and NELADC. In progressors, NELADC decreased at 6 weeks (P = 0.054), 3 months (P = 0.023) and 1 year/last (P = 0.078) as compared to baseline study and was also statistically significant as compared to non-progressors at 6 weeks (P = 0.047) and 3 months (P = 0.025). CELADC and NELADC appear to follow different trends over time for non-progressors and progressors with a stable to slightly progressive increase in non-progressors and a progressive decrease in progressors, especially early on. These findings suggest that DWI may be used as an additional imaging biomarker for early treatment response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Miller AB, Hoogstraten B, Staquet M et al (1981) Reporting results of cancer treatment. Cancer 47:207–214

    Article  CAS  PubMed  Google Scholar 

  2. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  CAS  PubMed  Google Scholar 

  3. Macdonald DR, Cascino TL, Schold SC et al (1990) Response criteria for phase II studies of malignant glioma. J Clin Oncol 8:1277–1280

    CAS  PubMed  Google Scholar 

  4. Henson JW, Ulmer S, Harris GJ (2008) Brain tumor imaging in clinical trials. AJNR Am J Neuroradiol 29(3):419–424

    Article  CAS  PubMed  Google Scholar 

  5. Sorensen AG, Batchelor TT, Wen PY et al (2008) Response criteria for glioma. Nat Clin Pract Oncol 5:634–644

    Article  PubMed  Google Scholar 

  6. Le Bihan D, Breton E, Lallemand D et al (1986) MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 161:401–407

    CAS  PubMed  Google Scholar 

  7. Tien RD, Felsberg GJ, Friedman H et al (1994) MR imaging of high-grade cerebral gliomas: value of diffusion weighted echoplanar pulse sequences. AJR Am J Roentgenol 162:671–677

    CAS  PubMed  Google Scholar 

  8. Brunberg JA, Chenevert TL, McKeever PE et al (1995) In vivo MR determination of water diffusion coefficients and diffusion anisotropy: correlation with structural alteration in gliomas of the cerebral hemispheres. AJNR Am J Neuroradiol 16:361–371

    CAS  PubMed  Google Scholar 

  9. Noguchi K, Watanabe N, Nagayoshi T et al (1999) Role of diffusion weighted echo-planar MRI in distinguishing between brain abscess and tumor: a preliminary report. Neuroradiology 41:171–174

    Article  CAS  PubMed  Google Scholar 

  10. Gupta RK, Sinha U, Cloughesy TF et al (1999) Inverse correlation between choline magnetic resonance spectroscopy signal intensity and the apparent diffusion coefficient in human glioma. Magn Reson Med 41:2–7

    Article  CAS  PubMed  Google Scholar 

  11. Stark Vance V (2005) Bevacizumab (Avastin) and CPT-11 (Camptosar) in the treatment of relapsed malignant glioma. Neurooncology 7:369

    Google Scholar 

  12. Pope WB, Lai A, Nghiemphu P et al (2006) MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66:1258–1260

    Article  CAS  PubMed  Google Scholar 

  13. Vredenburgh JJ, Desjardins A, Herndon JE et al (2007) Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant glioma. Clin Cancer Res 13:1253–1259

    Article  CAS  PubMed  Google Scholar 

  14. Holash J, Maisonpierre PC, Compton D et al (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994–1998

    Article  CAS  PubMed  Google Scholar 

  15. Kunkel P, Ulbricht U, Bohlen O et al (2001) Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61:6624–6628

    CAS  PubMed  Google Scholar 

  16. Rubenstein JL, Kim J, Ozawa T et al (2000) Anti-VEGF antibody treatment for glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2:306–314

    Article  CAS  PubMed  Google Scholar 

  17. Norden AD, Young GS, Setayesh K (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70(10):779–787

    Article  CAS  PubMed  Google Scholar 

  18. Fischer I, Cunliffe CH, Bollo RJ (2008) High-grade glioma before and after treatment with radiation and Avastin: initial observations. Neurooncology 10(5):700–708

    Google Scholar 

  19. Batchelor TT, Sorensen AG et al (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95

    Article  CAS  PubMed  Google Scholar 

  20. Moffat BA, Chenevert TL, Meyer CR et al (2006) The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 8:259–267

    Article  CAS  PubMed  Google Scholar 

  21. Ellika S, Jain R, Scarpace L, et al. (2007) Role of functional diffusion maps in predicting progression of low grade gliomas. In: Proceedings of American society of neuroradiology annual meeting 2007, p 242

  22. Ananthnarayan S, Bahng J, Roring J et al (2008) Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol 88:339–347

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Henry Ford Hospital, Detroit, MI, USA

    Rajan Jain, Lisa M. Scarpace, Shehanaz Ellika, Roy Torcuator, Lonni R. Schultz, David Hearshen & Tom Mikkelsen

Authors
  1. Rajan Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisa M. Scarpace
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shehanaz Ellika
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roy Torcuator
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lonni R. Schultz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David Hearshen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tom Mikkelsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rajan Jain.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jain, R., Scarpace, L.M., Ellika, S. et al. Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker. J Neurooncol 96, 423–431 (2010). https://doi.org/10.1007/s11060-009-9981-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-009-9981-6

Keywords

Search

Navigation